Navigation Links
Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
Date:11/6/2008

Atherotech to add new apoA1 measurement and apoB:apoA1 ratio to its comprehensive cholesterol test, further identifying patients at risk of

heart disease

BIRMINGHAM, Ala., Nov. 6 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP(R) Cholesterol Test in booth No. 2918 at the American Heart Association Scientific Sessions 2008. The annual meeting takes place Nov. 8-12 at the Ernest N. Morial Convention Center in New Orleans.

Atherotech representatives will be available to discuss the VAP Cholesterol Test during regular exhibit hours on October 9, 10 and 11 in booth No. 2918, and the VAP Test will be provided via blood draw to qualified attendees. Test results will be returned via mail after the conference.

The VAP (vertical auto profile) Test is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters - LDL, non-HDL and apoB - considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology.

"Detailed risk profiling through advanced lipid testing is changing the way we evaluate and manage heart disease risk," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The VAP Test is affordable, widely covered by insurance and will play an increasingly important role in heart attack and stroke prevention."

The VAP Test reports all 15 lipoprotein measurements with a single test, and unlike other lipid profiles, it directly measures LDL and HDL and includes Lp(a) and apoB as part of its standard test. Atherotech has announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early 2009. ApoA1 is the main component of protective HDL cholesterol and studies have shown that the apoB:apoA1 ratio may correlate better with increased risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL ratio.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test.

The VAP Cholesterol Test has been shown to identify significantly more patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test). Risks of both heart disease and diabetes can be reduced with the right preventive treatments, which is why more accurate diagnosis is critical.

The VAP Test is available nationwide. For more information call 877.901.8510 or visit http://www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP(R) technology, which directly measures the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for LDL measurement and the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Cholesterol Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
2. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
3. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
6. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
11. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
(Date:2/22/2017)... -- Scientists propose in Nature blocking a ... and maybe other lysosomal storage diseases as a possible ... therapies. An international research team led by ... included investigators from the University of Lübeck in ... The study was conducted in mouse models of lysosomal ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... of precision treatments for neurodegenerative diseases, today announced it has issued a scientific ... This is one of a series of commentaries from ProMIS’s scientific team offering ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... from around the world, is pleased to announce the launch of a new scholarship ... mathematics (STEM) fields. , This merit-based scholarship is open to all high school seniors, ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):